General
“Researchers have developed a deoxyribose-based topical gel that can restore hair growth by up to 90%.”
Plain restatementA research group has formulated a topical gel containing deoxyribose (2-deoxy-D-ribose) that, in published experiments, produced hair regrowth of a magnitude described around 80 to 90 percent. The claim does not state the species, model, duration, or what the percentage measures.
The study behind this viral post is real. Researchers at COMSATS University Islamabad and the University of Sheffield published a 2024 paper in Frontiers in Pharmacology showing that a topical gel containing deoxyribose, a sugar found in DNA, regrew fur in mice with testosterone-induced hair loss, performing about as well as minoxidil over 20 days. The problem is what the viral version leaves out. Every result comes from mice, not people, and the 80 to 90 percent figure in the paper describes how closely the gel matched minoxidil, not a guaranteed regrowth rate. The authors themselves wrote that the mechanism behind the effect has not yet been established. The first human trial testing this gel against minoxidil only began recruiting recently, so there is currently no human evidence of effectiveness or safety, and no approved product exists. Treat any gel sold today on the basis of this study as untested in humans.
[drifted from the evidence:] Researchers have developed a [drifted from the evidence:] deoxyribose-based topical gel that [drifted from the evidence:] can restore hair [drifted from the evidence:] growth by up to 90%.
A [added by the neutral restatement:] research group has formulated a topical gel [added by the neutral restatement:] containing deoxyribose (2-deoxy-D-ribose) that, [added by the neutral restatement:] in published experiments, produced hair [added by the neutral restatement:] regrowth of a magnitude described around 80 to 90 [added by the neutral restatement:] percent. The claim does not state the species, model, duration, or what the percentage measures.
Red-tinted words in the claim drifted from the evidence. Green-tinted words are what a neutral restatement needs.
The trace / claim to source
- The research is real, peer-reviewed, and from named institutions (COMSATS University Islamabad and the University of Sheffield).
- A topical deoxyribose gel was genuinely formulated and tested.
- A figure in the 80 to 90 percent range does appear in the primary literature.
- The gel's effect on hair growth was similar to minoxidil in the model used, matching the post caption's statement that effects were comparable to minoxidil in animal models.
- The post caption correctly specifies "in animal models" and "experimental studies," and correctly notes the non-hormonal framing.
- Increased blood vessel numbers were observed, consistent with the angiogenesis framing, though the authors stop short of confirming it as the mechanism.
- Species extrapolation: the headline claim text omits that every result is from mice. A reader encountering only "Researchers have developed a deoxyribose-based topical gel that can restore hair growth by up to 90%" has no way to know no human has been tested.
- Omitted qualifier and number conflation: the paper's "(80%–90%)" describes the similarity between minoxidil and 2dDR effects, and a separate 80 to 90 percent figure describes 2dDR's potency relative to VEGF for blood vessel formation. The viral framing "restore hair growth by up to 90%" collapses these into a single efficacy percentage that the abstract does not state in that form.
- Product framing: "have developed a topical gel that can restore hair growth" reads as an available or near-available treatment. The first human trial only began recently, and no regulator has approved any such product.
- Mechanism overstatement: the caption asserts the gel "helps deliver more oxygen and nutrients to the follicles," while the authors state the mechanism remains to be established.
- Temporal overreach: the linked ScienceAlert piece is dated 14 January 2026 but describes work from 2024. The post's presentation implies a fresh development rather than a two-year-old preclinical result recirculating.
- Whether the precise phrase "almost 90% coverage" appears verbatim in the paper's results section or is a journalist's rendering of a figure. It appears in secondary coverage; I could not retrieve the full results text to confirm the exact in-paper wording.
- Exact group sizes (number of mice per arm) and effect sizes with confidence intervals were not retrievable in the searches conducted.
- Whether topical 2dDR produces any effect in human scalp. No published human data exist.
- Safety in humans. No published human safety data; commercial products already marketed are outside the scope of the Sheffield/COMSATS research.
The study exists and is real. Researchers reported that a sugar called 2-deoxy-D-ribose (2dDR) can stimulate hair to regrow in mice, published in Frontiers in Pharmacology. The team prepared an alginate gel containing 2dDR, polypropylene glycol and phenoxyethanol; androgenic alopecia was induced in C57BL6 mice by intraperitoneally injecting testosterone, with a dihydrotestosterone-treated group as negative control, a minoxidil group as positive control, and groups receiving 2dDR gel or a 2dDR plus minoxidil combination. Each treatment was applied for 20 days. Both the 2dDR gel and minoxidil groups stimulated hair follicle morphogenesis, with stained skin sections showing increases in hair length, diameter, follicle density, anagen/telogen ratio, melanin coverage of the hair bulb, and number of blood vessels. The "90%" figure traces to two different statements in the paper, which are frequently conflated in coverage: - "The effects of the FDA-approved drug (minoxidil) on hair growth were similar to those of 2dDR (80%–90%)." This is a comparison between the two treatments, not a standalone regrowth percentage. - A separate figure from the group's earlier work: 2dDR is "80%-90% as effective as VEGF in the stimulation of neovascularization in in vitro models and in a chick bioassay." This is about blood vessel formation, not hair. - Secondary coverage adds a third figure: treated mice displayed "an almost 90% coverage of hair on their dorsal skin" within 21 days, equivalent to minoxidil-treated mice. The authors did not claim a mechanism. They concluded the gel "has potential for the treatment of androgenic alopecia" and possibly other alopecia conditions such as after chemotherapy, and stated that "the mechanism of activity of 2dDR remains to be established." No significant benefit was observed from combining minoxidil with 2dDR. Human evidence: as of this investigation, none has been published. A randomized controlled trial at Kasr El Aini Hospital is registered and recruiting to evaluate topical 2dDR hydrogel against topical minoxidil 5% in mild to moderate androgenetic alopecia in adults aged 18 to 50, with 60 participants randomized into two groups. The registry describes the 2dDR basis as "recent preclinical studies." Independent clinical commentary notes this is the first human clinical trial of a deoxyribose gel and that unregulated gels claiming to contain deoxyribose sugar have reached the market ahead of any human evidence of effectiveness or safety.
Complete reasoning
The reply is formatted for pasting into the thread where the claim is circulating.
Ask this case
Answers come only from the case file above; nothing is added.
Is the deoxyribose hair gel study real?
Yes. It is a peer-reviewed 2024 study published in Frontiers in Pharmacology by researchers at COMSATS University Islamabad and the University of Sheffield, who formulated a topical gel containing 2-deoxy-D-ribose and tested it.
Has this gel been tested on humans?
No. All results described in the study come from mice with testosterone-induced hair loss. A human trial comparing the gel to minoxidil has only recently begun recruiting, so no human effectiveness or safety data exist yet.
Where does the 90 percent figure actually come from?
It traces to a statement that 2dDR's effects on hair growth were similar to minoxidil, described as 80 to 90 percent, which is a comparison between two treatments, not a standalone regrowth rate. A separate 80 to 90 percent figure from earlier work describes 2dDR's potency relative to VEGF in blood vessel formation, not hair growth.
Do researchers know how the gel works?
No. The study authors state plainly that the mechanism of activity of 2dDR remains to be established, even though increased blood vessel numbers were observed in treated mice.
Can I buy this gel now and expect it to regrow hair?
The case file notes that unregulated gels claiming to contain deoxyribose have already reached the market, but no regulator has approved any such product and no published human data support effectiveness or safety.